Last updated on January 2019

A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B


Brief description of study

The purpose of the current Phase 1/2a single dose, dose-escalating study is to evaluate the acute safety, pharmacokinetics (PK) and pharmacodynamics (PD) properties of MOD-5014 in adult subjects with moderate/severe congenital hemophilia A or B. This will be a single-dose, open label, dose-escalating study. Each dose cohort will be concluded by a safety review, following which escalation to the next dose cohort will be approved.

Clinical Study Identifier: NCT02418793

Contact Investigators or Research Sites near you

Start Over

Nadia Ewing

City of Hope
Duarte, CA United States

Ingrid Mintautas

Children's Hospital Los Angeles
Los Angeles, CA United States

Doris Quon

Orthopaedic Hemophilia Treatment Center
Los Angeles, CA United States

Jonathan Ducore

University of California Davis Medical Center
Sacramento, CA United States

Lisa Boggio

Rush University Medical Center
Chicago, IL United States

Michael Tarantino

Bleeding & Clotting Disorders Institute
Peoria, IL United States

Amy Shapiro

Indiana Hemophilia & Thrombosis Center
Indianapolis, IN United States

Elaine Eyster

Penn State Milton S. Hershey Medical Center
Hershey, PA United States

Margaret Ragni

UPMC Presbyterian Shadyside
Pittsburgh, PA United States

Yu-Min Shen

UT Southwestern Medical Center
Dallas, TX United States

Miguel Escobar

The Gulf States Hemophilia and Thrombophilia Center
Houston, TX United States

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.